10-Q: Oncocyte's Losses Widen in Q3 2024 Amid Strategic Shift to Transplant Diagnostics

Oncocyte Corporation reported a net loss of $13.5 million in Q3 2024, a 108% increase from the same period last year, as the company pivots towards commercializing its transplant diagnostic tests.

Summary

• Oncocyte Corporation reported a net loss of $13.5 million in the third quarter of 2024, compared to $6.5 million in the same period of 2023.
• The increased loss is attributed to a shift in strategic focus towards commercializing transplant diagnostic tests, resulting in decreased Pharma Services revenue and increased research and development expenses.
• Revenue for Q3 2024 was $115,000, down 73% from $429,000 in Q3 2023, primarily due to decreased Pharma Services contracts.
• Research and development expenses rose by 29% to $2.8 million in Q3 2024, driven by the development of VitaGraft, DetermaIO, and DetermaCNI.
• Sales and marketing expenses increased by 46% to $1.0 million, reflecting efforts to commercialize the transplant business and support oncology efforts.
• The company completed a private placement in April 2024, raising $15.8 million, and an at-the-market offering in August 2024, raising $17,000 as of September 30, 2024.
• On October 4, 2024, Oncocyte completed another private placement, raising $10.2 million.
• Oncocyte is collaborating with Bio-Rad Laboratories, Inc. to develop and commercialize RUO and IVD kitted transplant products.

Sentiment

Score: 3

Explanation: The document presents a mixed picture of Oncocyte's financial performance and future prospects. While the company has made progress in developing and commercializing its transplant diagnostic tests and has secured partnerships, the significant increase in net loss, declining revenue, and substantial doubt about its ability to continue as a going concern raise serious concerns. The reliance on future capital raises and the uncertainty surrounding regulatory approvals and reimbursement coverage further contribute to a negative sentiment.

Positives

• Oncocyte has a partnership with Bio-Rad to develop and commercialize transplant diagnostic products.
• The company has received a positive coverage decision from MolDx for VitaGraft Kidney.
• VitaGraft Kidney became commercially available for ordering in January 2024.
• Oncocyte began commercializing GraftAssure, a research-use-only (RUO) test, in July 2024.
• The company is developing DetermaIO, a test to predict response to immunotherapies, which is available as part of an early access program.

Negatives

• Oncocyte reported a significant net loss of $13.5 million in Q3 2024.
• Revenue decreased substantially by 73% compared to the same period last year.
• The company is experiencing negative cash flows and has an accumulated deficit of $317.0 million as of September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company faces challenges in obtaining reimbursement coverage for its tests.
• Oncocyte may need to raise additional capital to finance its operations, which could dilute existing shareholders.

Risks

• Oncocyte has a history of operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
• The company may not be able to raise sufficient capital to finance its operations.
• Delays in obtaining regulatory approval or reimbursement coverage for its tests could hinder commercialization.
• The development and commercialization of new diagnostic tests are inherently uncertain.
• The company faces competition from other diagnostic companies.
• Changes in the regulatory environment, such as the FDA's final rule on Laboratory Developed Tests (LDTs), could impact the company's business.
• The company may be subject to enforcement action by the FDA if its RUO tests are deemed to be marketed for clinical diagnostic use.
• Oncocyte may be required to obtain premarket clearance or approval for its tests, which could be a time-consuming and expensive process.

Future Outlook

Oncocyte expects to continue incurring operating losses and negative cash flows for the foreseeable future. The company plans to focus on commercializing its transplant diagnostic tests, including VitaGraft and GraftAssure, and is also developing DetermaIO for the oncology market. Oncocyte may need to raise additional capital to fund its operations and achieve profitability.

Management Comments

• Our mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.
• We do this primarily by developing molecular diagnostic test kits that empower our customers to run their own tests to participate in the patient care value chain, which is counter-positioned with the central laboratory model.
• Our decentralized approach also puts testing in the hands of researchers to enable more studies, which inspires innovation, which can improve standards of care while also creating demand for more testing.
• We develop tests that measure both established biomarkers as well as pioneer the adoption of new and more effective biomarkers.
• We believe that combining innovative science with a simple, but disruptive, business model can create enormous value.
• This model is designed to empower doctors to reduce uncertainty to make better decisions to save lives as well as enable researchers to measure biomarkers to inspire innovation.
• Our operating premise is that democratizing access to testing to foster scientific innovation and better treatments ultimately reduces the cost of care, while expanding access and improving outcomes.
• At the heart, we are a science-driven organization that champions scientific integrity and inquiry.

Industry Context

Oncocyte operates in the molecular diagnostics industry, focusing on transplant diagnostics and oncology. The company's strategy of developing test kits aligns with the trend towards decentralized testing and personalized medicine. The partnership with Bio-Rad positions Oncocyte to compete in the growing market for transplant diagnostics. The company's focus on RUO tests allows it to generate revenue and gather data while pursuing regulatory approval for clinical use.

Comparison to Industry Standards

• Oncocyte's approach to developing transplant diagnostic test kits is similar to that of Natera, Inc., which offers the Prospera test, and CareDx, Inc., which offers the AlloSure and AlloMap tests.
• Natera, Inc reported revenues of $355.6 million in Q3 2024, with testing revenue of $337.5 million, primarily driven by Prospera.
• CareDx, Inc. reported total revenues of $70.4 million in Q3 2024, with testing services revenue of $56.5 million.
• Oncocyte's revenue in Q3 2024 was significantly lower than that of Natera and CareDx, reflecting its earlier stage of commercialization in the transplant diagnostics market.
• Oncocyte's focus on developing RUO tests is a common strategy in the diagnostics industry, allowing companies to generate revenue and gather data while pursuing regulatory approval for clinical use.
• Oncocyte's partnership with Bio-Rad is similar to other collaborations in the industry, such as Natera's partnership with BGI Genomics for the distribution of its Signatera test in China.

Corporate Governance

Related Party Transactions

• In April 2022, Oncocyte entered into a Securities Purchase Agreement with investors, including Broadwood and John Peter Gutfreund, a former director of Oncocyte, for the Series A Preferred Stock offering.
• In April 2023, Oncocyte redeemed all of the 588 shares of Series A Preferred Stock held by Mr. Gutfreund for $618,672.
• In April 2022, Oncocyte entered into an underwriting agreement pursuant to which the Company agreed to issue and sell certain shares of common stock and warrants to purchase common stock. Broadwood, Pura Vida, and Halle Special Situations Fund LLC participated in the offering.
• In April 2023, Oncocyte entered into a securities purchase agreement with certain investors, including Broadwood, Pura Vida, entities affiliated with AWM, Andrew Arno, and John Peter Gutfreund.
• In April 2024, Oncocyte consummated a private placement of its securities to certain investors, including Broadwood, entities affiliated with AWM, Bio-Rad, and Andrew Arno.
• In October 2024, Oncocyte consummated a private placement involving Broadwood, Bio-Rad, and Andrea James.
• The Company previously employed the son of Andrew Arno, Chairman of the Board.
• During 2024, the Company purchased $294,000 in laboratory equipment and incurred $230,000 in laboratory related costs from Bio-Rad. During 2024, the Company also made finance lease payments of $126,000 under four laboratory equipment leases from Bio-Rad with an initial capitalized total value of $976,000.
• On April 5, 2024, the Company entered into an agreement with Bio-Rad to collaborate in the development and the commercialization of RUO and IVD kitted transplant products.
• On November 8, 2024, the Company and Bio-Rad entered into a memorandum of understanding with respect to the Collaboration Agreement to establish additional activities to be performed by each party pursuant to the Collaboration Agreement.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises and the issuance of additional shares under the amended 2018 Incentive Plan.
• Employees: Potential impact from changes in business strategy and the need to reduce operating expenses if the company is unable to raise sufficient capital.
• Customers: Availability of new diagnostic tests for transplant monitoring and oncology.
• Suppliers: Continued business from Oncocyte's development and commercialization efforts.
• Creditors: Potential risk if the company is unable to meet its financial obligations.

Next Steps

• Oncocyte plans to continue developing and commercializing its transplant diagnostic tests, including VitaGraft and GraftAssure.
• The company will continue its collaboration with Bio-Rad to develop and commercialize RUO and IVD kitted transplant products.
• Oncocyte will pursue regulatory approval for the clinical use of its tests.
• The company will seek to obtain reimbursement coverage from Medicare and private insurers for its tests.
• Oncocyte will continue to develop DetermaIO for the oncology market.
• The company may need to raise additional capital to fund its operations and achieve profitability.

Key Dates

Keywords

diagnostics, transplant diagnostics, oncology, immunotherapy, biomarker, VitaGraft, GraftAssure, DetermaIO, DetermaCNI, companion diagnostics, precision medicine, molecular diagnostics, liquid biopsy, cell-free DNA, RUO, IVD, CLIA, FDA, pharmaceutical services, biotechnology